lidocaine has been researched along with Cognition Disorders in 12 studies
Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
Excerpt | Relevance | Reference |
---|---|---|
"Two middle aged female patients developed hallucinations and severe confusion with paranoid features during oral tocainide administration at recommended dosage levels." | 5.27 | Confusion and paranoia associated with oral tocainide. ( Clarke, CW; el-Mahdi, EO, 1985) |
"The lidocaine group had lower serum MDA levels than those in the control group." | 2.80 | Neuroprotective effects of intravenous lidocaine on early postoperative cognitive dysfunction in elderly patients following spine surgery. ( Chen, K; Li, J; Wei, P; Zheng, Q; Zhou, J, 2015) |
"Lidocaine was not neuroprotective." | 2.74 | Cerebral protection by lidocaine during cardiac operations: a follow-up study. ( Davies, E; Frampton, C; Gorman, DF; Grieve, D; Merry, AF; Mills, BP; Milsom, FP; Mitchell, SJ; Webster, CS; Willcox, TW, 2009) |
"Isoflurane may not cause long-lasting neuropathological changes." | 1.38 | Lidocaine attenuates cognitive impairment after isoflurane anesthesia in old rats. ( Cao, L; Li, J; Lin, D; Wang, Z; Washington, JM; Zuo, Z, 2012) |
"Two middle aged female patients developed hallucinations and severe confusion with paranoid features during oral tocainide administration at recommended dosage levels." | 1.27 | Confusion and paranoia associated with oral tocainide. ( Clarke, CW; el-Mahdi, EO, 1985) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (16.67) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (33.33) | 29.6817 |
2010's | 5 (41.67) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
Authors | Studies |
---|---|
Hung, KC | 1 |
Ho, CN | 1 |
Liu, WC | 1 |
Yew, M | 1 |
Chang, YJ | 1 |
Lin, YT | 1 |
Hung, IY | 1 |
Chen, JY | 1 |
Huang, PW | 1 |
Sun, CK | 1 |
Habibi, MR | 2 |
Habibi, V | 2 |
Habibi, A | 1 |
Soleimani, A | 1 |
Chen, K | 1 |
Wei, P | 1 |
Zheng, Q | 1 |
Zhou, J | 1 |
Li, J | 3 |
Peng, Y | 1 |
Zhang, W | 1 |
Zhou, X | 1 |
Ji, Y | 1 |
Kass, IS | 1 |
Han, R | 1 |
Gholipour Baradari, A | 1 |
Nouraei, SM | 1 |
Mathew, JP | 1 |
Mackensen, GB | 1 |
Phillips-Bute, B | 1 |
Grocott, HP | 1 |
Glower, DD | 1 |
Laskowitz, DT | 1 |
Blumenthal, JA | 1 |
Newman, MF | 1 |
Mitchell, SJ | 1 |
Merry, AF | 1 |
Frampton, C | 1 |
Davies, E | 1 |
Grieve, D | 1 |
Mills, BP | 1 |
Webster, CS | 1 |
Milsom, FP | 1 |
Willcox, TW | 1 |
Gorman, DF | 1 |
Lin, D | 1 |
Cao, L | 1 |
Wang, Z | 1 |
Washington, JM | 1 |
Zuo, Z | 1 |
Butterworth, J | 1 |
Hammon, JW | 1 |
Wang, D | 1 |
Wu, X | 1 |
Xiao, F | 1 |
Liu, X | 1 |
Meng, M | 1 |
Schneck, DW | 1 |
Clarke, CW | 1 |
el-Mahdi, EO | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
S100B Protein as Predictor of Cognitive Dysfunction After Robot-assisted Radical Prostatectomy: A Prospective Observational Study[NCT03018522] | 89 participants (Actual) | Observational | 2017-02-14 | Completed | |||
Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964] | 550 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
Continuous Cerebral Autoregulation Monitoring to Reduce Brain Injury From Cardiac Surgery[NCT00981474] | 460 participants (Actual) | Interventional | 2009-09-01 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.27 |
Placebo | -0.89 |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.57 |
Placebo | 0.16 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.09 |
Placebo | 0.07 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.07 |
Placebo | 0.07 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 6.3 |
Placebo | 6.96 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -10.98 |
Placebo | -11.67 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.07 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.04 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.02 |
Placebo | -0.02 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.04 |
Placebo | -0.01 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.71 |
Placebo | -1.16 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 1.23 |
Placebo | -0.49 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.20 |
Placebo | 0.03 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.95 |
Placebo | 1.59 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -6.70 |
Placebo | -6.39 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -7.12 |
Placebo | -6.31 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.39 |
Placebo | -1.48 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.67 |
Placebo | -0.8 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.46 |
Placebo | -1.02 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -3 |
Placebo | -3.21 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.15 |
Placebo | -0.31 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 2.46 |
Placebo | 2.1 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | Participants (Count of Participants) |
---|---|
Lidocaine | 87 |
Placebo | 83 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) | |
---|---|---|
1 year Change Work Activities | 1 year Change General health perception | |
Lidocaine | -1.37 | -0.28 |
Placebo | -1.42 | -0.43 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) | |
---|---|---|
6-Week Change Work activities | 6-Week Change General health perception | |
Lidocaine | 2.71 | -0.004 |
Placebo | 3 | -0.03 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.15 | 0.02 | -0.73 | -0.10 |
Placebo | -0.43 | -0.73 | -0.40 | 0.19 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -4.22 | -2.46 | -0.34 | 1.21 |
Placebo | -0.04 | 1.83 | 2.64 | 0.54 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -2.02 | 0.56 | 0.58 | 1.04 |
Placebo | -0.08 | 0.17 | 1.19 | -0.68 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.03 | 0.03 | 0.33 | 0.37 |
Placebo | 0.35 | 0.43 | 0.05 | 0.27 |
Subject developed acute kidney injury within 7 days after surgical procedure. Based on Kidney disease: Improving Global Outcomes (KDIGO) classification system. (NCT00981474)
Timeframe: 7 days after surgery
Intervention | Participants (Count of Participants) |
---|---|
Control | 56 |
Intervention | 62 |
The composite neurological outcome was composed of clinical stroke, or new ischemic lesions detected on postoperative brain diffusion weighted magnetic resonance imaging(DWI), or cognitive decline from baseline to 4-6 weeks after surgery. (NCT00981474)
Timeframe: Up to 6 weeks post-operative
Intervention | Participants (Count of Participants) |
---|---|
Usual Care Group (Control) | 79 |
Autoregulation Group | 70 |
Procedural insertion of intra-aortic balloon pump within 7 days after surgical procedure (NCT00981474)
Timeframe: 7 days after surgery
Intervention | Participants (Count of Participants) |
---|---|
Control | 19 |
Intervention | 14 |
Subjects need for mechanical lung ventilation more than 24 hours after planned surgical procedure. (NCT00981474)
Timeframe: Up to 28 days after surgery.
Intervention | Participants (Count of Participants) |
---|---|
Control | 22 |
Intervention | 13 |
Subject death within 28 days after surgical procedure (NCT00981474)
Timeframe: 28 days
Intervention | Participants (Count of Participants) |
---|---|
Control | 12 |
Intervention | 5 |
Use of multiple inotropic drugs greater than 24 hours after the planned surgical procedure until discharge from the hospital. (NCT00981474)
Timeframe: 7 days after surgery
Intervention | participants (Number) |
---|---|
Usual Care Group (Control) | 13 |
Autoregulation Group | 6 |
Subject diagnosis of multisystem organ failure after surgery. (NCT00981474)
Timeframe: Up to 28 days after surgery.
Intervention | Participants (Count of Participants) |
---|---|
Control | 7 |
Intervention | 2 |
Subjects requiring new renal replacement therapy prior to discharge from hospital (NCT00981474)
Timeframe: Up to 28 days after surgery.
Intervention | Participants (Count of Participants) |
---|---|
Control | 6 |
Intervention | 4 |
Clinical diagnosis of postoperative atrial fibrillation from date of surgical procedure to discharge from the hospital. (NCT00981474)
Timeframe: Up to 28 days after surgery.
Intervention | Participants (Count of Participants) |
---|---|
Control | 89 |
Intervention | 79 |
Assessed with Confusion Assessment Method or Confusion Assessment Method-ICU along with adjudication by team of experts (NCT00981474)
Timeframe: Postoperative days 1-4
Intervention | Participants (Count of Participants) |
---|---|
Usual Care Group (Control) | 34 |
Autoregulation Group | 19 |
Clinical diagnosis of sepsis from time of surgical procedure to discharge from the hospital. (NCT00981474)
Timeframe: Up to 28 days after surgery.
Intervention | Participants (Count of Participants) |
---|---|
Control | 7 |
Intervention | 2 |
3 reviews available for lidocaine and Cognition Disorders
Article | Year |
---|---|
Prophylactic effect of intravenous lidocaine against cognitive deficit after cardiac surgery: A PRISMA-compliant meta-analysis and trial sequential analysis.
Topics: Adult; Anesthetics, Local; Cardiac Surgical Procedures; Cognition; Cognition Disorders; Humans; Lido | 2022 |
Lidocaine dose-response effect on postoperative cognitive deficit: meta-analysis and meta-regression.
Topics: Cognition Disorders; Coronary Artery Bypass; Dose-Response Relationship, Drug; Humans; Lidocaine; Ne | 2018 |
Administration of lidocaine to prevent cognitive deficit in patients undergoing coronary artery bypass grafting and valve plasty: a systematic review and meta-analysis.
Topics: Cardiac Valve Annuloplasty; Cognition Disorders; Coronary Artery Bypass; Humans; Lidocaine; Voltage- | 2017 |
5 trials available for lidocaine and Cognition Disorders
Article | Year |
---|---|
Neuroprotective effects of intravenous lidocaine on early postoperative cognitive dysfunction in elderly patients following spine surgery.
Topics: Aged; Aged, 80 and over; Anesthesia, General; Cognition Disorders; Female; Humans; Infusions, Intrav | 2015 |
Lidocaine Did Not Reduce Neuropsychological-Cognitive Decline in Patients 6 Months After Supratentorial Tumor Surgery: A Randomized, Controlled Trial.
Topics: Adult; Anesthetics, Local; Cognition; Cognition Disorders; Double-Blind Method; Female; Humans; Lido | 2016 |
Randomized, double-blinded, placebo controlled study of neuroprotection with lidocaine in cardiac surgery.
Topics: Aged; Anesthesia; Anesthetics, Local; Cardiac Surgical Procedures; Cognition Disorders; Double-Blind | 2009 |
Randomized, double-blinded, placebo controlled study of neuroprotection with lidocaine in cardiac surgery.
Topics: Aged; Anesthesia; Anesthetics, Local; Cardiac Surgical Procedures; Cognition Disorders; Double-Blind | 2009 |
Randomized, double-blinded, placebo controlled study of neuroprotection with lidocaine in cardiac surgery.
Topics: Aged; Anesthesia; Anesthetics, Local; Cardiac Surgical Procedures; Cognition Disorders; Double-Blind | 2009 |
Randomized, double-blinded, placebo controlled study of neuroprotection with lidocaine in cardiac surgery.
Topics: Aged; Anesthesia; Anesthetics, Local; Cardiac Surgical Procedures; Cognition Disorders; Double-Blind | 2009 |
Cerebral protection by lidocaine during cardiac operations: a follow-up study.
Topics: Brain Diseases; Cardiac Surgical Procedures; Cognition Disorders; Double-Blind Method; Female; Follo | 2009 |
The effect of lidocaine on early postoperative cognitive dysfunction after coronary artery bypass surgery.
Topics: Aged; Anesthesia; Anesthetics, Local; Cardiopulmonary Bypass; Cognition Disorders; Coronary Artery B | 2002 |
4 other studies available for lidocaine and Cognition Disorders
Article | Year |
---|---|
Lidocaine attenuates cognitive impairment after isoflurane anesthesia in old rats.
Topics: Aging; Amyloid beta-Peptides; Anesthetics, Inhalation; Anesthetics, Local; Animals; Brain; Cognition | 2012 |
Lidocaine for neuroprotection: more evidence of efficacy.
Topics: Cardiac Surgical Procedures; Cognition Disorders; Humans; Lidocaine; Neuroprotective Agents; Neurops | 2002 |
Therapeutic rounds at the Milton S. Hershey Medical Center: central nervous system toxicity caused by lidocaine.
Topics: Cognition Disorders; Confusion; Drug Interactions; Heart Failure; Humans; Lidocaine; Male; Middle Ag | 1983 |
Confusion and paranoia associated with oral tocainide.
Topics: Administration, Oral; Cognition Disorders; Confusion; Female; Humans; Lidocaine; Middle Aged; Parano | 1985 |